Karyopharm Therapeutics Inc. (KPTI) News
Filter KPTI News Items
KPTI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KPTI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KPTI News From Around the Web
Below are the latest news stories about KARYOPHARM THERAPEUTICS INC that investors may wish to consider to help them evaluate KPTI as an investment opportunity.
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stands against other best penny stocks to buy according to the media. Small-Cap Stocks Outlook for 2025 On December 24, Global […] |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 101,250 shares of Karyopharm's common stock and an aggregate of 108,540 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of December 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducemen |
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial OfficerKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. |
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. |
Karyopharm Therapeutics Provides Endometrial Cancer Program UpdateKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it is in discussions and has an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial. In light of this, Karyopharm does not plan to discuss its endometrial cancer program during the Piper |
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 36th Annual Healthcare Conference in a fireside chat on Tuesday, December 3 at 11:30 a.m. ET in New York, NY. |
Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer s |
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and ExpositionKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego, CA. |
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) defied analyst predictions to release its third-quarter results, which... |
Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsKaryopharm Therapeutics ( NASDAQ:KPTI ) Third Quarter 2024 Results Key Financial Results Revenue: US$38.8m (up 7.7... |